Why the study?
The COMPASS trial was stopped early because combination therapy reduced ischemic strokes, prompting an analysis of the association between low-dose rivaroxaban with or without aspirin and specific ischemic stroke subtypes.
Does low-dose rivaroxaban with or without aspirin reduce the risk of specific ischemic stroke subtypes in patients with stable atherosclerotic vascular disease compared to aspirin alone?
Population
27 395 patients with stable atherosclerotic vascular disease across 33 countries
Comparison
Rivaroxaban plus aspirin vs rivaroxaban alone vs aspirin alone
Design
Secondary analysis of a multicenter, double-blind, randomized, placebo-controlled trial
Follow-up
Followed up to February 6, 2017
Authors
Loading...
Supports rivaroxaban plus aspirin for stroke prevention in CAD/PAD; extends COMPASS to cardioembolic subtypes.
Does low-dose rivaroxaban with or without aspirin reduce the risk of specific ischemic stroke subtypes in patients with stable atherosclerotic vascular disease compared to aspirin alone?
In patients with stable atherosclerosis, adding low-dose rivaroxaban to aspirin significantly reduces the risk of cardioembolic and undetermined source ischemic strokes.
Perera et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: